Van de Werf, F. J., Armstrong, P. W., Levy, J., Granger, C. B., Califf, R. M., Adams, P. X., … Vernier, E. D. (2004). 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. In Journal of the American College of Cardiology (Vol. 43, pp. A474–A474). Elsevier BV. https://doi.org/10.1016/s0735-1097(04)92006-2

Van de Werf, Frans J., Paul W. Armstrong, Jerrold Levy, Christopher B. Granger, Robert M. Califf, Peter X. Adams, Michael VanderLaan, Christopher Mojcik, Thomas G. Todaro, and Edward D. Vernier. “810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction.” In Journal of the American College of Cardiology, 43:A474–A474. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)92006-2.

Van de Werf FJ, Armstrong PW, Levy J, Granger CB, Califf RM, Adams PX, et al. 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. In: Journal of the American College of Cardiology. Elsevier BV; 2004. p. A474–A474.

Van de Werf, Frans J., et al. “810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction.” Journal of the American College of Cardiology, vol. 43, no. 5, Elsevier BV, 2004, pp. A474–A474. Crossref, doi:10.1016/s0735-1097(04)92006-2.

Van de Werf FJ, Armstrong PW, Levy J, Granger CB, Califf RM, Adams PX, VanderLaan M, Mojcik C, Todaro TG, Vernier ED. 810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. Journal of the American College of Cardiology. Elsevier BV; 2004. p. A474–A474.